This is a preview of subscription content, log in via an institution to check access.
References
Barnett PS, Coskeran P, Bouloux C. A dose-response and tolerability study of the beta-3 adrenergic agonist, SR 58611. Journal of Endocrinology 144 (Suppl.): abstr. P308, Mar 1995
Barnett PS, Coskeran P, Bouloux C. Chronic administration of the new selective beta-3 adrenergic agonist, SR 58611A. 10th International Congress of Endocrinology II: 986, 12 Jun 1996
Simiand J, Keane PE, Guitard J, et al. Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical beta-adrenoceptors. European Journal of Pharmacology 219: 193–201, 25 Aug 1992
Manara L, Bianchetti A, Croci T. The atypical beta-adre noceptor agonist SR 58611A is less effective than clenbuterol, albuterol and ritodrine in reducing rat water diuresis. FASEB Journal 6: A1290, 26 Feb 1992
De Ponti F, Cosentino M, Costa A. Inhibitory effects of SR-58611A on canine colonic motility: evidence for a role of beta-3-adrenoceptors. British Journal of Pharmacology 114: 1447–1453, Apr 1995
Coruzzi G, Bertaccini G. The beta-3-adrenoceptor agonist SR58611A inhibits gastric acid secretion in the conscious cat. Naunyn-Schmiedeberg’s Archives of Pharmacology 356: 263–265, Aug 1997
Nisoli E, Tonello C, Carruba MO. SR 58611A: a novel thermogenic beta-adrenoceptor agonist. European Journal of Pharmacology 259: 181–186, 1 Jul 1994
Rights and permissions
About this article
Cite this article
SR 58611A. Drugs R&D 4, 380–382 (2003). https://doi.org/10.2165/00126839-200304060-00012
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200304060-00012